ULURU Inc. Announces Poster Presentation of Dr. Gregory Bohn

- Cost Benefits of Altrazeal(TM) Highlighted

- Evidence of Reduced Pain and Accelerated Healing Presented

Oct 23, 2009, 13:17 ET from ULURU Inc.

ADDISON, Texas, Oct. 23 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced that Gregory Bohn, M.D., FACS, Medical Director, Trinity Wound Care and Hyperbaric Medicine, Bettendorf, Iowa, has presented nine clinical posters at the 24th Annual "Clinical Symposium on Advances in Skin and Wound Care" being held in San Antonio, Texas.

Highlights of the clinical experience presented by Dr. Bohn's poster presentations include:

  • A stagnated traumatic wound that was treated with Altrazeal(TM) eliminated the need for a skin graft procedure
  • Using Altrazeal(TM) in combination with total contact casts decreased "days to heal" from 41 days to 15 days in Wagner grade 2 neuropathic diabetic foot ulcers
  • Chronic venous stasis ulcer patients that had not healed in 30 months after treatments including skin graft and bioengineered skin graft healed after treatment with Altrazeal(TM)

Commenting on Altrazeal(TM), Dr. Gregory Bohn stated, "Altrazeal(TM) can be a work horse in the wound care field. I have seen dramatic clinical results on many different types of problematic wounds. I have also found that Altrazeal(TM) increases wound care dressing wear time which has been instrumental in increasing patients' treatment compliance and enabling costs to be constrained within Medicare monthly limits for stomal and wound care supplies. Additionally, combining Altrazeal(TM) with contact casts for Wagner grade 2 diabetic foot ulcers has reduced our days to heal from 41 days to 15.2 days representing a substantial cost savings and avoiding morbidity for our diabetic patients."

Also included in the poster presentations by Dr. Bohn was evidence of the benefits of using Altrazeal(TM), including:

  • Reduction in pain and improvement in quality of life
    • Eliminated the need for patients to use oral narcotics to manage pain
  • Provides significant cost benefits
    • Documented $1,260 monthly savings for a patient with a peristomal pyoderma
    • Reduced healing times for diabetic foot ulcer patients resulting in significant savings
  • Long wear time for Altrazeal(TM) allows greater versatility in wound treatment and combination with other treatments including contact casts

Altrazeal(TM), a transforming powder dressing which is produced using our patented Nanoflex(TM) Technology, is suitable for exuding wounds such as burns, abrasions, trauma, skin graft donor sites, surgical wounds and chronic slow-healing wounds such as diabetic foot ulcers, pressure ulcers and venous ulcers. Altrazeal(TM) is an innovative breakthrough, designed for greater effectiveness in wound closure by promoting an optimal moist wound healing environment, reducing pain and enhancing patient comfort, ease of application and removal and, in most cases, not requiring a secondary dressing.

Renaat Van den Hooff, President and CEO of ULURU Inc. further commented, "We are delighted with the results achieved by Dr. Bohn and the extensive supporting clinical evidence he has generated. The cost effectiveness, accelerated healing, pain reduction and quality of life evidence provides strong support for our sales and marketing activities. This positive clinical evidence using Atlrazeal(TM) includes many different wound types including diabetic foot ulcers, venous ulcers, burns, chronic traumatic wounds and degenerative skin conditions."

About ULURU Inc.:

ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex(TM) Aggregate technology and OraDisc(TM) transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.uluruinc.com. For further information about Altrazeal(TM), please visit www.Altrazeal.com.

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, including but not limited to statements made relating to the benefits, effectiveness, success in wound healing, including pain reduction and accelerated healing, clinical outcomes, and suitability of Altrazeal(TM), pharmacoeconomic benefits and the success of our clinical efforts. These statements are subject to numerous risks and uncertainties, including but not limited to the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and other reports filed by us with the Securities and Exchange Commission.

    Contact: Company
    Renaat E. Van den Hooff
    President & CEO
    Terry K. Wallberg
    Vice President & CFO
    (214) 905-5145